Obesity Pipeline Insight

DelveInsight’s, “Obesity - Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Obesity: Understanding

Obesity: Overview

Obesity is the excessive or abnormal accumulation of fat or adipose tissue in the body that impairs health via its association with the risk of development of diabetes mellitus, cardiovascular disease, hypertension, and hyperlipidemia. It is a significant public health epidemic which has progressively worsened over the past 50 years. Obesity is a complex disease and has a multifactorial etiology. It is the second most common cause of preventable death after smoking. A 5% to 10% weight loss can significantly improve health, quality of life, and economic burden of an individual and a country as a whole.  Obesity is the result of an imbalance between daily energy intake and energy expenditure, resulting in excessive weight gain. Obesity is a multifactorial disease caused by a myriad of genetic, cultural, and societal factors.  Various genetic studies have shown that obesity is extremely heritable, with numerous genes identified with adiposity and weight gain. Other causes of obesity include reduced physical activity, insomnia, endocrine disorders, medications, the accessibility and consumption of excess carbohydrates and high-sugar foods, and decreased energy metabolism. 

Obesity is defined as abnormal or excessive fat accumulation that poses a health risk, with a body mass index (BMI) over 25 considered overweight and over 30 classified as obese. Diagnosis involves assessing BMI, where a BMI of 30 or higher indicates obesity, and measuring waist size to evaluate visceral fat. Health professionals also consider other health issues like high blood pressure, cholesterol levels, and diabetes when diagnosing obesity. It is the second most common cause of preventable death, which is associated with the risk of developing inflammatory components, directly and indirectly, related to cardiovascular disease, diabetes mellitus, respiratory problems, psychological issues, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. It imposes a significant public health epidemic that has progressively worsened over the past semi-centennial. An increase in obesity has been observed in children and adults of both genders and is prevalent in both developed and developing countries.

The treatment of obesity typically involves a combination of lifestyle changes, medication, and in some cases, weight-loss procedures. Lifestyle changes include adopting a healthy, reduced-calorie diet, increasing physical activity, and receiving psychological support if needed. Medications like orlistat may be recommended if lifestyle changes alone are not effective. Weight-loss surgeries or procedures like endoscopic sleeve gastroplasty and intragastric balloon insertion can be options for severe obesity cases. It is essential to work with healthcare professionals to set realistic weight-loss goals and maintain long-term changes to improve overall health and reduce the risk of obesity-related complications.

"Obesity- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obesity pipeline landscape is provided which includes the disease overview and Obesity treatment guidelines. The assessment part of the report embraces, in depth Obesity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Obesity R&D. The therapies under development are focused on novel approaches to treat/improve Obesity.

Obesity Emerging Drugs Chapters

This segment of the Obesity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Obesity Emerging Drugs

• Survodutide: Zealand Pharma

Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity.

• Ecnoglutide: Sciwind Biosciences

Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity. 

• CT-868: Carmot Therapeutics

CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868’s effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity. 

• DD01: D&D Pharmatech

DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase II clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD). 

• ERX1000: ERX Pharmaceuticals

ERX-1000, a first-in-class leptin sensitizer, is in development for the treatment of obesity and related diseases. By using a systems-biology approach, ERX scientific co-founder Dr. Umut Ozcan identified ERX-1000, a first-in-class leptin sensitizer. While ERX-1000 is highly effective at reducing appetite and decreasing weight in diet-induced obese mouse models (an experimental model of human obesity), it does not have any effect on leptin-deficient obese mice, obese mice lacking leptin signaling (genetically deficient in leptin or its receptor), or non-obese mice, demonstrating that ERX-1000 is a true leptin sensitizer. Administration of ERX-1000 in a preclinical laboratory setting to diet-induced severely obese mice reduced appetite up to 80% and led to a 45% decrease in bodyweight in 21 days, a level of weight loss that has not been previously observed in any drug in preclinical studies or in animal models of invasive bariatric surgery. 

The clinical development program for ERX-1000 is designed to support registration for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity. A first-in-human Phase I, double-blind, placebo-controlled, single and multiple oral dose study has been conducted in healthy non-obese and obese subjects to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ERX-1000. Preliminary data from this clinical trial have shown dose responsive weight loss in a 4-week treatment period, thereby yielding initial proof of efficacy for ERX-1000 in obese humans. Currently the drug is in Phase I stage of its development for the treatment of Obesity. 

Further product details are provided in the report……..

Obesity: Therapeutic Assessment

This segment of the report provides insights about the different Obesity drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Obesity

There are approx. 80+ key companies which are developing the therapies for Obesity. The companies which have their Obesity drug candidates in the most advanced stage, i.e. Phase III include, Zealand Pharma.

Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Obesity: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obesity therapeutic drugs key players involved in developing key drugs. 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obesity drugs.

Obesity Report Insights

• Obesity Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Obesity Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Obesity drugs?
• How many Obesity drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obesity?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Obesity therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Obesity and their status?
• What are the key designations that have been granted to the emerging drugs?